Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Incyte's Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo in the US, adding to its current use in atopic dermatitis.

Incyte could be a few month away from a second FDA approval for its Opzelura cream that would make it the first medical treatment to re-pigment the skin of people with vitiligo. The FDA has kicked ...

Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I first noticed some repigmentation, particularly on my face ...

For Lisa, life with nonsegmental vitiligo has been a roller coaster ... To help repigment my skin, I use Opzelura ® (ruxolitinib) cream 1.5%. After a few months of using it consistently twice ...

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin re ...

Existing therapy has limitations In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the ...

The company is banking on Opzelura sales to drive growth as its cancer drug Jakafi is set to lose key patents in 2028. Opzelura is used for the treatment of skin conditions called vitiligo and mild-to ...